AOTMiT: Transparency Council Discusses, Among Other Things, Obesity, Asthma, and Osteoporosis

The agenda includes:

1. Preparation of a position paper on the evaluation of Brineura (cerliponasum alfa) as part of the drug program “Treatment of patients with type 2 neuronal lipofuscinosis (ICD-10: E75.4).”
2. Preparation of a position statement on the evaluation of Mounjaro KwikPen (tirzepatidum) as part of the drug program “Treatment of Patients with Obesity (ICD-10: E.66).”
3. Preparation of a position statement on the evaluation of Keytruda (pembrolizumab) under the B.52 drug program. “Treatment of patients with squamous cell carcinoma of the head and neck (ICD-10 C01, C02, C03, C04, C05, C06, C09, C10, C12, C13, C14, C32).
4. Preparation of a position statement on the evaluation of Izamby (denosumab) for the indication: treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures (defined as a T-score of -2.5 or lower or the occurrence of an osteoporotic fracture).
5. Preparation of an opinion on the appropriateness of introducing changes to the B.44 drug program , “Treatment of patients with severe asthma (ICD-10: J45, J82)”
6. Preparation of an opinion on the draft health policy program of the local government entity titled “Health Policy Program for the Rehabilitation of Świnoujście Residents Aged 70 and Older for the Years 2026–2028.”

Source: AOTMiT

.